Drugs / 8M2D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07568041 | Sep 2026 → Sep 2027 expected | Alzheimer disease | Cenna Biosciences Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 8M2D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07568041 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT07568041 ↗ |